376 related articles for article (PubMed ID: 36077371)
1. The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.
O'Connell C; VandenHeuvel S; Kamat A; Raghavan S; Godin B
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077371
[TBL] [Abstract][Full Text] [Related]
2. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Moser TL; Young TN; Rodriguez GC; Pizzo SV; Bast RC; Stack MS
Int J Cancer; 1994 Feb; 56(4):552-9. PubMed ID: 8112891
[TBL] [Abstract][Full Text] [Related]
3. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion.
Ellerbroek SM; Hudson LG; Stack MS
Int J Cancer; 1998 Oct; 78(3):331-7. PubMed ID: 9766568
[TBL] [Abstract][Full Text] [Related]
4. Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer.
Ahmed N; Pansino F; Baker M; Rice G; Quinn M
J Cell Biochem; 2002; 84(4):675-86. PubMed ID: 11835393
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
Rosanò L; Varmi M; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
Cancer Res; 2001 Nov; 61(22):8340-6. PubMed ID: 11719468
[TBL] [Abstract][Full Text] [Related]
6. Role of Serine Proteases at the Tumor-Stroma Interface.
Tagirasa R; Yoo E
Front Immunol; 2022; 13():832418. PubMed ID: 35222418
[TBL] [Abstract][Full Text] [Related]
7. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
8. Downregulated Dual-Specificity Protein Phosphatase 1 in Ovarian Carcinoma: A Comprehensive Study With Multiple Methods.
Liang ZQ; He RQ; Luo JY; Huang ZG; Li J; Zhong LY; Chen JH; Huang SN; Shi L; Wei KL; Zeng JH; Zeng JJ; Chen G
Pathol Oncol Res; 2022; 28():1610404. PubMed ID: 35911442
[No Abstract] [Full Text] [Related]
9. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.
Yang Y; Zhao T; Chen Q; Li Y; Xiao Z; Xiang Y; Wang B; Qiu Y; Tu S; Jiang Y; Nan Y; Huang Q; Ai K
Adv Sci (Weinh); 2022 Oct; 9(28):e2202797. PubMed ID: 35869032
[TBL] [Abstract][Full Text] [Related]
11. Epithelial ovarian cancer experimental models.
Lengyel E; Burdette JE; Kenny HA; Matei D; Pilrose J; Haluska P; Nephew KP; Hales DB; Stack MS
Oncogene; 2014 Jul; 33(28):3619-33. PubMed ID: 23934194
[TBL] [Abstract][Full Text] [Related]
12. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.
Johnson EL; Singh R; Singh S; Johnson-Holiday CM; Grizzle WE; Partridge EE; Lillard JW
World J Surg Oncol; 2010 Jul; 8():62. PubMed ID: 20649989
[TBL] [Abstract][Full Text] [Related]
13. The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.
Baci D; Bosi A; Gallazzi M; Rizzi M; Noonan DM; Poggi A; Bruno A; Mortara L
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32354198
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF-β1/thrombospondin-1 axis.
Kitami K; Yoshihara M; Tamauchi S; Sugiyama M; Koya Y; Yamakita Y; Fujimoto H; Iyoshi S; Uno K; Mogi K; Ikeda Y; Yokoi A; Yoshikawa N; Nishino K; Niimi K; Nawa A; Enomoto A; Kajiyama H
Matrix Biol; 2022 May; 109():70-90. PubMed ID: 35339636
[TBL] [Abstract][Full Text] [Related]
15. Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation.
Mir H; Kaur G; Kapur N; Bae S; Lillard JW; Singh S
Sci Rep; 2019 Feb; 9(1):2527. PubMed ID: 30792527
[TBL] [Abstract][Full Text] [Related]
16. Biochemical characterization of primary peritoneal carcinoma cell adhesion, migration, and proteinase activity.
Fishman DA; Chilukuri K; Stack MS
Gynecol Oncol; 1997 Nov; 67(2):193-9. PubMed ID: 9367707
[TBL] [Abstract][Full Text] [Related]
17. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
Yoshihara M; Kajiyama H; Yokoi A; Sugiyama M; Koya Y; Yamakita Y; Liu W; Nakamura K; Moriyama Y; Yasui H; Suzuki S; Yamamoto Y; Ricciardelli C; Nawa A; Shibata K; Kikkawa F
Int J Cancer; 2020 Apr; 146(8):2268-2280. PubMed ID: 31904865
[TBL] [Abstract][Full Text] [Related]
18. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Al Sawah E; Chen X; Marchion DC; Xiong Y; Ramirez IJ; Abbasi F; Bou Zgheib N; Chon HS; Wenham RM; Apte SM; Judson PL; Lancaster JM
Gynecol Oncol; 2013 Oct; 131(1):207-12. PubMed ID: 23877012
[TBL] [Abstract][Full Text] [Related]
19. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis.
Mitra AK; Chiang CY; Tiwari P; Tomar S; Watters KM; Peter ME; Lengyel E
Oncogene; 2015 Nov; 34(48):5923-32. PubMed ID: 25798837
[TBL] [Abstract][Full Text] [Related]
20. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.
Kenny HA; Kaur S; Coussens LM; Lengyel E
J Clin Invest; 2008 Apr; 118(4):1367-79. PubMed ID: 18340378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
